Home > Insider Trading > Filing (0001209191-11-049251)

Filing Details

Accession Number:: 0001209191-11-049251
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-09-28 13:55:33
Reporting Period:: 2011-09-26

Filing Date:: 2011-09-28
Accepted Time:: 2011-09-28 13:55:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1135906	Zalicus Inc.	ZLCS	Pharmaceutical Preparations (2834)	043514457

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1173408	L.p. Iii Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1173409	L.p. Iii-Qp Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249063	Mpm Bioventures Iii Parallel Fund, L.p.	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249133	Mpm Bioventures Iii Gmbh & Co. Beteiligungs Kg	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249141	Mpm Asset Management Investors 2003 Bviii Llc	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249143	L.p. Gp Iii Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249147	Mpm Bioventures Iii Llc	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1263048	Mpm Asset Management Llc	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-09-26	210,000	$1.11	14,423,961	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-09-27	200,000	$1.09	14,223,961	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The shares were sold as follows: 174,808 by MPM BioVentures III-QP, L.P. ("BV III QP"), 11,754 by MPM BioVentures III, L.P. ("BV III"), 3,385 by MPM Asset Management Investors 2003 BVIII LLC ("AM 2003"), 5,279 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 14,774 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG").
Represents weighted average sales price. The shares were sold at prices ranging from $1.07 to $1.16. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 11,946,398 by BV III QP, 802,078 by BV III, 230,999 by AM 2003, 359,799 by BV Parallel, 1,008,372 by BV KG and 76,315 by MPM Asset Management LLC ("MPM AM"). MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2003. Luke Evnin and Ansbert Gadicke are members of MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 166,485 by BV III QP, 11,194 by BV III, 3,223 by AM 2003, 5,028 by BV Parallel and 14,070 by BV KG.
Represents weighted average sales price. The shares were sold at prices ranging from $1.01 to $1.13. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 11,779,913 by BV III QP, 790,884 by BV III, 227,776 by AM 2003, 354,771 by BV Parallel, 994,302 by BV KG and 76,315 by MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.